High-dose aducanumab delays clinical decline across multiple domains in early AD
25 Aug 2021
byElaine Soliven
Treatment with high-dose aducanumab shows less clinical decline across individual items or domains of cognition, function, and behaviour compared with placebo in patients with early symptomatic Alzheimer’s disease (AD), according to the EMERGE* study presented at AAIC 2021.